Literature DB >> 19250370

Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme.

H Tiller1, M K Killie, B Skogen, P Øian, A Husebekk.   

Abstract

The implementation of an antenatal screening programme for neonatal alloimmune thrombocytopenia (NAIT) is currently under debate. We evaluated the detection rate for NAIT in a nonscreened population of 661,200 births where NAIT was diagnosed on clinical indication. We did a cross-sectional comparison with a population of 100,448 human platelet antigen 1a (HPA1a)-screened pregnancies from three of the five health regions in Norway. In a nonscreening situation, 7.5 cases of NAIT were detected per year compared with 53 cases when screening was applied. The detection rate of NAIT in Norway was therefore 14% of the expected rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250370     DOI: 10.1111/j.1471-0528.2008.02068.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  4 in total

1.  Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin.

Authors:  N Margreth Van Der Lugt; Marije M Kamphuis; Noortje P M Paridaans; Anouk Figee; Dick Oepkes; Frans J Walther; Enrico Lopriore
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

Review 2.  Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

Authors:  Heidi Tiller; Anne Husebekk; Maria Therese Ahlen; Tor B Stuge; Bjørn Skogen
Journal:  Int J Womens Health       Date:  2017-04-19

3.  Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.

Authors:  Anno Saris; Ivan Peyron; Pieter F van der Meer; Tor B Stuge; Jaap Jan Zwaginga; S Marieke van Ham; Anja Ten Brinke
Journal:  Front Immunol       Date:  2018-06-05       Impact factor: 7.561

Review 4.  Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention.

Authors:  Ewa Brojer; Anne Husebekk; Marzena Dębska; Małgorzata Uhrynowska; Katarzyna Guz; Agnieszka Orzińska; Romuald Dębski; Krystyna Maślanka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-11-12       Impact factor: 4.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.